279 related articles for article (PubMed ID: 17699281)
21. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial.
Szeto CC; Chow KM; Kwan BC; Chung KY; Leung CB; Li PK
Am J Kidney Dis; 2008 May; 51(5):724-31. PubMed ID: 18436082
[TBL] [Abstract][Full Text] [Related]
22. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy.
du Buf-Vereijken PW; Branten AJ; Wetzels JF
Am J Kidney Dis; 2005 Dec; 46(6):1012-29. PubMed ID: 16310567
[TBL] [Abstract][Full Text] [Related]
23. Rituximab in post allogeneic hematopoietic stem cell transplantation membranous nephropathy: a case report.
Vischini G; Cudillo L; Ferrannini M; Di Daniele N; Cerretti R; Arcese W
J Nephrol; 2009; 22(1):160-3. PubMed ID: 19229832
[TBL] [Abstract][Full Text] [Related]
24. Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy.
Gansevoort RT; Heeg JE; Vriesendorp R; de Zeeuw D; de Jong PE
Nephrol Dial Transplant; 1992; 7 Suppl 1():91-6. PubMed ID: 1337189
[TBL] [Abstract][Full Text] [Related]
25. Low glomerular density is a risk factor for progression in idiopathic membranous nephropathy.
Tsuboi N; Kawamura T; Miyazaki Y; Utsunomiya Y; Hosoya T
Nephrol Dial Transplant; 2011 Nov; 26(11):3555-60. PubMed ID: 21771759
[TBL] [Abstract][Full Text] [Related]
26. Detection and clinical significance of glomerular M-type phospholipase A
Liu H; Luo W; Gong S; Ding X
Intern Med J; 2016 Nov; 46(11):1318-1322. PubMed ID: 27554390
[TBL] [Abstract][Full Text] [Related]
27. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
[TBL] [Abstract][Full Text] [Related]
28. Rituximab treatment of fibrillary glomerulonephritis.
Collins M; Navaneethan SD; Chung M; Sloand J; Goldman B; Appel G; Rovin BH
Am J Kidney Dis; 2008 Dec; 52(6):1158-62. PubMed ID: 18823685
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of glomerular and tubulointerstitial morphometry in idiopathic membranous nephropathy.
Horvatic I; Ljubanovic DG; Bulimbasic S; Knotek M; Prkacin I; Tisljar M; Galesic K
Pathol Res Pract; 2012 Nov; 208(11):662-7. PubMed ID: 22995635
[TBL] [Abstract][Full Text] [Related]
30. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab.
Guiard E; Karras A; Plaisier E; Duong Van Huyen JP; Fakhouri F; Rougier JP; Noel LH; Callard P; Delahousse M; Ronco P
Clin J Am Soc Nephrol; 2011 Jul; 6(7):1609-16. PubMed ID: 21700823
[TBL] [Abstract][Full Text] [Related]
31. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.
Jha V; Ganguli A; Saha TK; Kohli HS; Sud K; Gupta KL; Joshi K; Sakhuja V
J Am Soc Nephrol; 2007 Jun; 18(6):1899-904. PubMed ID: 17494881
[TBL] [Abstract][Full Text] [Related]
32. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome.
Ruggenenti P; Mosconi L; Vendramin G; Moriggi M; Remuzzi A; Sangalli F; Remuzzi G
Am J Kidney Dis; 2000 Mar; 35(3):381-91. PubMed ID: 10692263
[TBL] [Abstract][Full Text] [Related]
33. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.
Steinmetz OM; Lange-Hüsken F; Turner JE; Vernauer A; Helmchen U; Stahl RA; Thaiss F; Panzer U
Transplantation; 2007 Oct; 84(7):842-50. PubMed ID: 17984836
[TBL] [Abstract][Full Text] [Related]
34. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
Bazzi C; Rizza V; Paparella M; Casellato D; Napodano P; Olivieri G; D'Amico G
J Nephrol; 2009; 22(3):387-96. PubMed ID: 19557716
[TBL] [Abstract][Full Text] [Related]
35. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome.
Chen A; Frank R; Vento S; Crosby V; Chandra M; Gauthier B; Valderrama E; Trachtman H
BMC Nephrol; 2007 Aug; 8():11. PubMed ID: 17683621
[TBL] [Abstract][Full Text] [Related]
36. Rituximab for idiopathic membranous nephropathy.
Remuzzi G; Chiurchiu C; Abbate M; Brusegan V; Bontempelli M; Ruggenenti P
Lancet; 2002 Sep; 360(9337):923-4. PubMed ID: 12354476
[TBL] [Abstract][Full Text] [Related]
37. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study.
Branten AJ; du Buf-Vereijken PW; Klasen IS; Bosch FH; Feith GW; Hollander DA; Wetzels JF
J Am Soc Nephrol; 2005 Jan; 16(1):169-74. PubMed ID: 15563570
[TBL] [Abstract][Full Text] [Related]
38. An overview of immunosuppressive therapy in idiopathic membranous nephropathy.
Maas R; Hofstra JM; Wetzels JF
Minerva Med; 2012 Aug; 103(4):253-66. PubMed ID: 22805618
[TBL] [Abstract][Full Text] [Related]
39. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
40. Urinary excretion of low-molecular-weight proteins as prognostic markers in IgA nephropathy.
Peters HP; van den Brand JA; Wetzels JF
Neth J Med; 2009 Feb; 67(2):54-61. PubMed ID: 19299847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
